{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:31:32Z","timestamp":1772213492460,"version":"3.50.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","award":["High Impact Clinical Research and Scientific Pilot Project award"],"award-info":[{"award-number":["High Impact Clinical Research and Scientific Pilot Project award"]}],"id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","award":["High Impact Clinical Research and Scientific Pilot Project award"],"award-info":[{"award-number":["High Impact Clinical Research and Scientific Pilot Project award"]}],"id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI114780"],"award-info":[{"award-number":["R01-AI114780"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21-AI142198"],"award-info":[{"award-number":["R21-AI142198"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA575198"],"award-info":[{"award-number":["MDA575198"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"crossref","award":["SPIN award"],"award-info":[{"award-number":["SPIN award"]}],"id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG Research fellowship (FI 2471\/1-1)"],"award-info":[{"award-number":["DFG Research fellowship (FI 2471\/1-1)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement deficiency resulting in reduced complement activity, due to consumption, during episodes of disease activity. It is not clear whether complement activity in MG patients associates with measurements of disease activity or the titer of circulating pathogenic AChR autoantibodies. To explore such associations, as a means to identify a candidate biomarker, we measured complement activity in AChR MG samples (N = 51) using a CH50 hemolysis assay, then tested associations between these values and both clinical status and AChR autoantibody titer. The majority of the study subjects (88.2%) had complement activity within the range defined by healthy controls, while six patients (11.8%) showed reduced activity. No significant association between complement activity and disease status or AChR autoantibody titer was observed.<\/jats:p>","DOI":"10.1371\/journal.pone.0264489","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T13:25:31Z","timestamp":1647350731000},"page":"e0264489","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Myasthenia gravis complement activity is independent of autoantibody titer and disease severity"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-4103","authenticated-orcid":true,"given":"Miriam L.","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle D.","family":"Hoarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douangsone D.","family":"Vadysirisack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bailey","family":"Munro-Sheldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"issue":"10","key":"pone.0264489.ref001","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"A. Vincent","year":"2002","journal-title":"Nature reviews Immunology"},{"key":"pone.0264489.ref002","volume-title":"Immunobiology: The Immune System in Health and Disease","author":"CA Janeway","year":"2001"},{"issue":"1","key":"pone.0264489.ref003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"JR Dunkelberger","year":"2010","journal-title":"Cell Research"},{"issue":"14","key":"pone.0264489.ref004","first-page":"1058","article-title":"Complement. First of two parts","volume":"344","author":"MJ Walport","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0264489.ref005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"JV Sarma","year":"2011","journal-title":"Cell and tissue research"},{"issue":"5","key":"pone.0264489.ref006","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1073\/pnas.1616998114","article-title":"Structure and activation of C1, the complex initiating the classical pathway of the complement cascade","volume":"114","author":"SA Mortensen","year":"2017","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"pone.0264489.ref007","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The Central Role of the Alternative Complement Pathway in Human Disease","volume":"176","author":"JM Thurman","year":"2006","journal-title":"The Journal of Immunology"},{"issue":"5","key":"pone.0264489.ref008","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nri800","article-title":"Evolution of the lectin-complement pathway and its role in innate immunity","volume":"2","author":"T. Fujita","year":"2002","journal-title":"Nature reviews Immunology"},{"issue":"3","key":"pone.0264489.ref009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0025-7125(16)31028-8","article-title":"The hereditary and acquired deficiencies of complement","volume":"69","author":"SR Nusinow","year":"1985","journal-title":"Med Clin North Am"},{"issue":"4","key":"pone.0264489.ref010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaci.2004.02.003","article-title":"Clinical and laboratory evaluation of complement deficiency","volume":"113","author":"L Wen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"pone.0264489.ref011","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJM199203263261306","article-title":"Molecular Heterogeneity of C2","volume":"326","author":"CA Johnson","year":"1992","journal-title":"Deficiency. New England Journal of Medicine"},{"issue":"Suppl 3","key":"pone.0264489.ref012","first-page":"S95","article-title":"Complement deficiency: predisposing factor to autoimmune syndromes","volume":"7","author":"JP Atkinson","year":"1989","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"pone.0264489.ref013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00003246-198205000-00004","article-title":"Complement activation in septic shock due to gram-negative and gram-positive bacteria","volume":"10","author":"C Le\u00f3n","year":"1982","journal-title":"Crit Care Med"},{"issue":"10","key":"pone.0264489.ref014","first-page":"456","article-title":"Serum complement levels in patients with rheumatoid arthritis and vasculitis","volume":"80","author":"K. Tomooka","year":"1989","journal-title":"Fukuoka Igaku Zasshi"},{"issue":"2","key":"pone.0264489.ref015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/art.1780190206","article-title":"Intraarticular activation of the complement system in patients with juvenile rheumatoid arthritis","volume":"19","author":"RI Rynes","year":"1976","journal-title":"Arthritis & Rheumatism"},{"issue":"37","key":"pone.0264489.ref016","doi-asserted-by":"crossref","first-page":"e4871","DOI":"10.1097\/MD.0000000000004871","article-title":"Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis","volume":"95","author":"S Fukui","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"pone.0264489.ref017","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s10067-019-04636-9","article-title":"Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study","volume":"38","author":"L Garc\u00eda","year":"2019","journal-title":"Clinical Rheumatology"},{"issue":"2","key":"pone.0264489.ref018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/39.2.133","article-title":"Links between complement abnormalities and systemic lupus erythematosus","volume":"39","author":"MC Pickering","year":"2000","journal-title":"Rheumatology"},{"issue":"2","key":"pone.0264489.ref019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02099020","article-title":"Lupus diseases associated with hereditary and acquired deficiencies of complement","volume":"9","author":"V. Agnello","year":"1986","journal-title":"Springer Seminars in Immunopathology"},{"key":"pone.0264489.ref020","first-page":"135","volume":"15","author":"WLO Nastuk","year":"1956","journal-title":"Reduction in Serum Complement Concentration in Myasthenia Gravis Federation Proceedings"},{"issue":"7","key":"pone.0264489.ref021","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/jnnp.42.7.595","article-title":"Immune complexes in myasthenia gravis","volume":"42","author":"WM Behan","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"pone.0264489.ref022","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"AG Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"pone.0264489.ref023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.29.2.179","article-title":"Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor","volume":"29","author":"AG Engel","year":"1979","journal-title":"Neurology"},{"issue":"6","key":"pone.0264489.ref024","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"S Nakano","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"pone.0264489.ref025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"K Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"pone.0264489.ref026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3181\/00379727-105-26051","article-title":"Immunofluorescence Demonstration of a Muscle Binding, Complement-Fixing Serum Globulin Fraction in Myasthenia Gravis","volume":"105","author":"AJL Strauss","year":"1960","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"issue":"5","key":"pone.0264489.ref027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/jnnp.41.5.394","article-title":"Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications","volume":"41","author":"AK Lefvert","year":"1978","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"11","key":"pone.0264489.ref028","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"JM Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"pone.0264489.ref029","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1749-6632.1981.tb33741.x","article-title":"Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer","volume":"377","author":"RS Tindall","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"pone.0264489.ref030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.43.7.590","article-title":"Anti-acetylcholine receptor antibodies","volume":"43","author":"A Vincent","year":"1980","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"issue":"10","key":"pone.0264489.ref031","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0161-5890(97)00091-6","article-title":"Effect of whole and fractionated intravenous immunoglobulin on complement in vitro","volume":"34","author":"TE Mollnes","year":"1997","journal-title":"Mol Immunol"},{"issue":"10","key":"pone.0264489.ref032","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1432-2277.2010.01088.x","article-title":"Effect of IVIG administration on complement activation and HLA antibody levels","volume":"23","author":"T Machimoto","year":"2010","journal-title":"Transpl Int"},{"issue":"6","key":"pone.0264489.ref033","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"TM Burns","year":"2008","journal-title":"Muscle & nerve"},{"issue":"37","key":"pone.0264489.ref034","first-page":"1923","article-title":"Measuring the 50% haemolytic complement (CH50) activity of serum","author":"M. Costabile","year":"2010","journal-title":"Journal of visualized experiments: JoVE"},{"issue":"15 Supplement","key":"pone.0264489.ref035","doi-asserted-by":"crossref","first-page":"S31.006","DOI":"10.1212\/WNL.90.15_supplement.S31.006","article-title":"RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006)","volume":"90","author":"JF Howard","year":"2018","journal-title":"Neurology"},{"key":"pone.0264489.ref036","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.molimm.2017.06.186","article-title":"RA101495 abolishes residual complement activity observed in the presence of eculizumab","volume":"89","author":"A Ricardo","year":"2017","journal-title":"Molecular immunology"},{"issue":"5","key":"pone.0264489.ref037","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"JF Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"pone.0264489.ref038","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","article-title":"Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population","volume":"9","author":"M Gaya da Costa","year":"2018","journal-title":"Frontiers in immunology"},{"issue":"6","key":"pone.0264489.ref039","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1081-1206(10)61257-4","article-title":"Complement determinations in human disease","volume":"93","author":"MM Glovsky","year":"2004","journal-title":"Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology"},{"key":"pone.0264489.ref040","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"F Aguirre","year":"2020","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"1","key":"pone.0264489.ref041","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Y Ozawa","year":"2021","journal-title":"European journal of neurology"},{"issue":"1\u20132","key":"pone.0264489.ref042","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"F Romi","year":"2005","journal-title":"Journal of neuroimmunology"},{"issue":"5","key":"pone.0264489.ref043","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"A Liu","year":"2009","journal-title":"Muscle & nerve"},{"issue":"12","key":"pone.0264489.ref044","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"JF Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0264489.ref045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"S Muppidi","year":"2019","journal-title":"Muscle & nerve"},{"issue":"4158","key":"pone.0264489.ref046","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"RR Almon","year":"1974","journal-title":"Science (New York, NY)"},{"issue":"20","key":"pone.0264489.ref047","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"DB Drachman","year":"1978","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T05:32:41Z","timestamp":1726810361000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264489"}},"subtitle":[],"editor":[{"given":"G\u00fcher","family":"Saruhan-Direskeneli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264489","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.15.21249875","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}